This paper presents new methods for determining potential glioma biomarkers that can support the diagnosis of this tumor. The presented methods of determination have demonstrated the ability to distinguish advanced glioma grades (G3 and G4) from the control group (K) and mild grades (G1 and G2) based on the concentration values of the determined analytes. The blood-brain barrier probably makes it difficult to quantitatively detect biomarkers in milder grades of the disease, which limits their use in early diagnosis. However, studies indicate that the concentrations of the determined potential biomarkers are independent of the IDH 1/2 mutation and show positive correlations with each other, which suggests their potential synergistic effect. Due to the high sensitivity and specificity of the proposed methods, confirmed by ROC analysis, they can support imaging techniques in distinguishing between the grades of glioma advancement, especially in differentiating between grades G2 and G3.
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.